Abbott Laboratories: First-Quarter 2014 Form 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories filed its unaudited Form 10-Q for the three months ended March 31, 2014. Abbott develops, manufactures and sells health care products through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Products segments, along with non-reportable businesses. The results reflect Abbott after its January 1, 2013 separation of AbbVie Inc.
Financial Performance and Position
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Net sales | $5.244 billion | $5.378 billion | Down 2.5% |
| Operating earnings | $451 million | $615 million | Down 26.7% |
| Earnings from continuing operations | $339 million | $544 million | Down 37.7% |
| Net earnings | $375 million | $544 million | Down 31.1% |
| Diluted earnings per share | $0.24 | $0.34 | Down $0.10 |
| Net cash from operating activities | $336 million | $460 million | Down $124 million |
- Gross margin was 49.6%, compared with 51.1% in the prior-year quarter. Operating margin was approximately 8.6%, compared with 11.4%; net margin was approximately 7.2%, compared with 10.1%.
- Sales excluding foreign-exchange effects increased 0.5%; unfavorable currency movements reduced reported sales by approximately 3.0%.
- Segment sales were $1.151 billion for Established Pharmaceuticals, $1.631 billion for Nutritionals, $1.117 billion for Diagnostics and $738 million for Vascular Products. Diagnostics grew 2.6% reported and 5.1% excluding foreign exchange; Nutritionals declined 4.0% reported and 1.7% excluding foreign exchange.
- Research and development expense increased 11.6% to $387 million, primarily because of restructuring charges. Selling, general and administrative expense decreased 1.3% to $1.762 billion.
- Cash and cash equivalents were $2.060 billion at March 31, 2014, supplemented by $4.987 billion of short-term investments. Working capital was $7.7 billion, down from $9.7 billion at year-end.
- Total reported short-term borrowings, current long-term debt and long-term debt were approximately $7.765 billion. Abbott had $5.0 billion of unused credit lines supporting commercial paper arrangements. Long-term debt ratings were A+ from Standard & Poor’s and A1 from Moody’s.
- Capital expenditures were $255 million. Cash used in investing activities was $595 million, and cash used in financing activities was $1.152 billion.
- Abbott repurchased 54.6 million shares for approximately $2.1 billion and paid $343 million of dividends. The declared quarterly dividend increased to $0.22 per share from $0.14.
Material Changes Versus the Prior Comparable Period
- Reported sales declined primarily because of currency headwinds. Underlying growth was driven by Diagnostics, while Nutritionals was affected by lower pediatric sales following a supplier recall in certain international markets.
- Operating earnings declined substantially as gross margin compressed, restructuring costs increased and foreign exchange adversely affected operations.
- Taxes on continuing operations included a $71 million benefit from favorable resolution of prior-year tax positions. The prior-year quarter included an approximately $103 million tax benefit from retroactive U.S. tax law changes, making the comparison less representative.
- First-quarter 2014 net earnings included $36 million of net tax benefits classified as discontinued operations, primarily related to pre-separation AbbVie tax matters.
- Operating cash flow declined partly because Abbott contributed $312 million to defined benefit plans in 2014 versus $208 million in 2013. The 2013 period also included approximately $233 million of one-time cash outflows related to the AbbVie separation.
- Share repurchases and dividends reduced cash balances and shareholders’ investment. Treasury shares increased to approximately 187.7 million from 137.7 million at year-end.
Guidance, Outlook, Risks and Unusual Items
- Management stated that annual operating cash flow is expected to continue exceeding annual capital expenditures and cash dividends, but the filing does not provide specific full-year earnings or revenue guidance.
- Abbott recorded approximately $80 million of new restructuring charges for vascular, diagnostics and nutritional operations, plus $25 million of additional charges across functional areas. The filing indicates these initiatives are intended to reduce costs and improve efficiency.
- Abbott expects transitional services with AbbVie to continue for up to 24 months, with a possible one-year extension. Remaining assets and liabilities from the separation were expected to transfer to AbbVie during 2014.
- Foreign exchange, health-care regulation, pricing pressure, competitive launches, international economic conditions and government reimbursement remain key risks. Abbott specifically noted government receivables in Italy, Spain, Portugal and Greece, which represented 9% of total net trade receivables at March 31, 2014.
- Legal and environmental matters had an estimated possible loss range of approximately $70 million to $90 million, with an accrued balance of approximately $80 million. Management did not expect these matters to materially affect financial position, cash flows or results of operations.
- Abbott believed gross unrecognized tax benefits could decrease by up to $350 million, including cash adjustments, within the following twelve months as tax matters are resolved.
- No goodwill impairment was recorded. Estimated intangible-asset amortization expense was approximately $655 million for 2014.
- In April 2014, after the quarter ended, the Dutch Supreme Court rejected Medinol’s appeal in a stent patent case, resulting in a final noninfringement determination for Abbott’s stents.
Important Facts for Investors to Verify
- Assess the sustainability of reported earnings excluding the $71 million continuing-operations tax benefit and the $36 million discontinued-operations tax benefit.
- Monitor whether Diagnostics growth and emerging-market performance offset continued Nutritionals disruption, pharmaceutical pricing pressure and vascular competition.
- Verify the effect of foreign exchange on sales, gross margin and operating earnings, particularly across international businesses.
- Track restructuring charges, expected savings and any additional cash requirements.
- Review liquidity after the $2.1 billion share repurchase program, the higher dividend and increased short-term borrowings.
- Follow the timing and financial effects of remaining AbbVie asset transfers, transitional services and retained tax obligations.
- Evaluate potential changes in tax liabilities, litigation and environmental accruals, including the possible resolution of up to $350 million of unrecognized tax benefits.